NCT02771509 is a Phase 2 clinical trial of ANG-3777 in Acute Kidney Injury, sponsored by Angion Biomedica Corp.

Who is sponsoring NCT02771509?

NCT02771509 is sponsored by Angion Biomedica Corp.

What drugs are being tested in NCT02771509?

Interventions in NCT02771509: ANG-3777, Placebo.

What condition does NCT02771509 study?

NCT02771509 studies Acute Kidney Injury.

Is NCT02771509 still recruiting?

NCT02771509 is currently status unknown. Last updated 9 July 2021.

Last reviewed 2021-07-09 · How we verify

NCT02771509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery

Status unknown Phase 2 Last updated 9 July 2021

What this trial tests

Phase 2 trial testing ANG-3777 in Acute Kidney Injury in 275 participants. Status unknown.

Timeline

24 February 2017

Primary endpoint
1 August 2021

1 August 2021

Quick facts

Lead sponsor	Angion Biomedica Corp
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	275
Start date	24 February 2017
Primary completion	1 August 2021
Estimated completion	1 August 2021
Sites	40 locations across United States, Brazil, Canada, Georgia

Drugs / interventions tested

ANG-3777 — full drug profile →
Placebo

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

Angion Biomedica Corp — full company profile →

Who can join

18 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The mean AUC of the percent increase in serum creatinine above baseline
Time frame: starting from 24 hr after the end of CPB through Day 6

Sponsor's own description

The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Perioperative Acute Kidney Injury.
Gumbert SD, Kork F, Jackson ML, Vanga N, et al · · 2020 · cited 209× · PMID 31687986 · DOI 10.1097/aln.0000000000002968
Fibroblasts in liver cancer: functions and therapeutic translation.
Affo S, Filliol A, Gores GJ, Schwabe RF. · · 2023 · cited 34× · PMID 37385282 · DOI 10.1016/s2468-1253(23)00111-5
New drugs for acute kidney injury.
Pickkers P, Murray PT, Ostermann M. · · 2022 · cited 33× · PMID 35999470 · DOI 10.1007/s00134-022-06859-y
Acute kidney injury: emerging pharmacotherapies in current clinical trials.
Benoit SW, Devarajan P. · · 2018 · cited 33× · PMID 28601936 · DOI 10.1007/s00467-017-3695-3
Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury.
Ayad S, Neylan JF, Mayne TJ, Gouveia D, et al · · 2020 · cited 10× · PMID 33305126 · DOI 10.1016/j.ekir.2020.09.031
New drugs for acute kidney injury.
Hariri G, Legrand M. · · 2025 · cited 8× · PMID 39872831 · DOI 10.1016/j.jointm.2024.08.001
Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways.
Liu Z, Zhang X, Wang Y, Tai Y, et al · · 2023 · cited 3× · PMID 37627244 · DOI 10.3390/biom13081179
The Growth Factors: Potential Biomarkers and Therapeutic Targets in Kidney Diseases.
Tang W, Zhang Y, Cui S, Yi F. · · 2022 · cited 3× · PMID 36466071 · DOI 10.1159/000526208

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other Angion Biomedica Corp trials

Trials by the same sponsor.

NCT04939116 — Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease · Phase 2 · unknown
NCT04459676 — Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia · Phase 2 · unknown
NCT04196179 — ANG-3070 in Healthy Adult Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02771509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Angion Biomedica Corp
Last refreshed: 9 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02771509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing